Dengue Vaccines Market Introduction and Overview
According to SPER Market Research, the Global Dengue Vaccines Market is estimated to reach USD 1813.95 million by 2033 with a CAGR of 13.11%.
Dengue vaccines are designed to prevent dengue fever, a viral illness transmitted by Aedes mosquitoes, characterized by high fever, severe headache, pain behind the eyes, joint and muscle pain, rash, and bleeding tendencies. These vaccines aim to reduce the incidence of dengue and its severe manifestations, such as dengue haemorrhagic fever and dengue shock syndrome. The development of dengue vaccines has been driven by the need to combat a disease that affects millions globally, especially in tropical and subtropical regions. Currently, several dengue vaccines are available or in development, including the Dengvaxia (CYD-TDV) by Sanofi Pasteur, which is a live attenuated tetravalent vaccine designed to protect against all four dengue virus serotypes. Their deployment in endemic areas is crucial for controlling dengue outbreaks and reducing the public health burden associated with this mosquito-borne illness.
- April 2021; Takeda Drug Organization Restricted reported the endorsement of its TAK-003 dengue antibody up-and-comer by the European Medications Organization (EMA), which is at present being scrutinized for the avoidance of any episodes in people matured 4 to 60 years. The organization additionally means to apply for administrative endorsements in Argentina, Brazil, Columbia, Indonesia, Malaysia, Mexico, Singapore, Sri Lanka, and Thailand through 2021.
Market Opportunities and Challenges
Opportunities- Propels in biotechnology and immunization fabricating processes have brought about the advancement of more powerful and more secure dengue antibodies. Advancements like recombinant DNA innovations and inventive conveyance instruments further develop immunization adequacy and openness. These specialized progressions energize ventures and speed up market development. Expanded worldwide travel and quick urbanization add to the improvement of dengue infection, intensifying the interest in inoculations. Voyagers to endemic districts and thickly populated metropolitan regions are bound to become contaminated. Subsequently, there is a more noteworthy accentuation on preventive immunization, which drives market interest. The specific predominance of dengue and its financial impact is obscure. In excess of 125 nations are accepted to universally be dengue-endemic. In this way, the ascent in the pervasiveness pace of the sickness will drive the market during the estimated time frame.
Challenges- Exploring the complex administrative scene represents a significant obstacle for dengue immunization creators. Acquiring consent from wellbeing specialists requires broad exploration and approval, which can defer market section and raise costs, making it hard to rapidly sendoff original antibodies. Giving far-reaching conveyance and openness to dengue immunizations in endemic regions presents strategic hindrances. Deficient medical services framework, cold chain limitations, and political unsteadiness in certain spots can all hinder the fruitful execution of immunization programs, decreasing in the general market entrance. Administrative obstacles in immunization entrance are one of the key difficulties upsetting the dengue antibody market development. Sellers are confronting trouble in getting endorsements for the send-off of antibodies in a few dengue-endemic nations due to the idea of dengue serotypes in various nations.
Market Competitive Landscape
The Global Dengue Vaccines Market is a highly competitive arena due to the presence of multiple global and regional companies in the competitive environment. Leading companies in the industry are Butantan Institute, GeneOne Life Science Inc., GlaxoSmithKline Plc, Mylan N.V., Medigen Vaccine Biologics Corporation, Merck and Co. Inc., Nunn’s Home Medical Equipment Company Ltd., Panacea Biotec Limited, Sanofi Pasteur Limited, Serum Institute of India Pvt Ltd.
Scope of the report:
| Report Metric | Details |
| Market size available for years | 2020-2033 |
| Base year considered | 2023 |
| Forecast period | 2024-2033 |
| Segments covered | By Type of Vaccine, By Vaccine Phase, By Distribution Channel
|
| Regions covered | North America, Asia-Pacific, Latin America, Middle East & Africa and Europe
|
| Companies Covered | Butantan Institute, GeneOne Life Science Inc., GlaxoSmithKline Plc, Mylan N.V., Medigen Vaccine Biologics Corporation, Merck and Co. Inc., Nunn’s Home Medical Equipment Company Ltd., Panacea Biotec Limited, Sanofi Pasteur Limited, Serum Institute of India Pvt Ltd.
|
COVID-19 Impact on Global Dengue Vaccines Market
The episode of Coronavirus impacted all nations lockdown guidelines in different nations were loose, which prompted the resumption of business exercises offering fundamental administrations. Consequently, the resumption of drug assembling will take special care of the interest for dengue antibodies in North America and register speeding up market development during the conjecture time frame. The quick development in illness commonness is strikingly driving the dengue immunization market development, in spite of the fact that variables, such as administrative obstacles in antibody entrance might obstruct market development.
Key Target Audience:
- Healthcare Providers
- Government Health Agencies
- Pharmaceutical Companies
- Research Institutions
- Non-Governmental Organizations (NGOs)
- Health Insurance Providers
Our in-depth analysis of the Dengue Vaccines Market includes the following segments:
|
By Type of Vaccine:
|
Live Attenuated Vaccines
Recombinant Vaccines
|
|
By Vaccine Phase:
|
Phase I
Phase II
Phase III
|
|
By Distribution Channel:
|
Synthetic
Bio-Based
|
Key Topics Covered in the Report:
- Global Dengue Vaccines Market Size (FY’2024-FY’2033)
- Overview of Global Dengue Vaccines Market
- Segmentation of Global Dengue Vaccines Market by Type of Vaccine (Live Attenuated Vaccines, Recombinant Vaccines)
- Segmentation of Global Dengue Vaccines Market by Vaccine Phase (P Phase I, Phase II, Phase III)
- Segmentation of Global Dengue Vaccines Market by Distribution Channel (Hospitals, Clinics, Retail Pharmacies)
- Statistical Snap of Global Dengue Vaccines Market
- Expansion Analysis of Global Dengue Vaccines Market
- Problems and Obstacles in Global Dengue Vaccines Market
- Competitive Landscape in the Global Dengue Vaccines Market
- Impact of COVID-19 and Demonetization on Global Dengue Vaccines Market
- Details on Current Investment in Global Dengue Vaccines Market
- Competitive Analysis of Global Dengue Vaccines Market
- Prominent Players in the Global Dengue Vaccines Market
- SWOT Analysis of Global Dengue Vaccines Market
- Global Dengue Vaccines Market Future Outlook and Projections (FY’2024-FY’2033)
- Recommendations from Analyst
1. Introduction
1.1. Scope of the report
1.2. Market segment analysis
2. Research Methodology
2.1. Research data source
2.1.1. Secondary Data
2.1.2. Primary Data
2.1.3. SPER’s internal database
2.1.4. Premium insight from KOL’s
2.2. Market size estimation
2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation
3. Executive Summary
4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1. Drivers
4.1.2. Restraints
4.1.3. Opportunities
4.1.4. Challenges
4.2. COVID-19 Impacts of the Global Dengue Vaccines Market
5. Market variable and outlook
5.1. SWOT Analysis
5.1.1. Strengths
5.1.2. Weaknesses
5.1.3. Opportunities
5.1.4. Threats
5.2. PESTEL Analysis
5.2.1. Political Landscape
5.2.2. Economic Landscape
5.2.3. Social Landscape
5.2.4. Technological Landscape
5.2.5. Environmental Landscape
5.2.6. Legal Landscape
5.3. PORTER’s Five Forces
5.3.1. Bargaining power of suppliers
5.3.2. Bargaining power of buyers
5.3.3. Threat of Substitute
5.3.4. Threat of new entrant
5.3.5. Competitive rivalry
5.4. Heat Map Analysis
6. Competitive Landscape
6.1. Global Dengue Vaccines Market Manufacturing Base Distribution, Sales Area, Product Type of Vaccine
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Dengue Vaccines Market
7. Global Dengue Vaccines Market, By Type of Vaccine (USD Million) 2020-2033
7.1. Global Dengue Vaccines Market Size, Share and Forecast, By Type of Vaccine, 2020-2026
7.2. Global Dengue Vaccines Market Size, Share and Forecast, By Type of Vaccine, 2027-2033
7.3. Live Attenuated Vaccines
7.4. Recombinant Vaccines
8. Global Dengue Vaccines Market, By Vaccine Phase (USD Million) 2020-2033
8.1. Global Dengue Vaccines Market Size, Share and Forecast, By Vaccine Phase, 2020-2026
8.2. Global Dengue Vaccines Market Size, Share and Forecast, By Vaccine Phase, 2027-2033
8.3. Phase I
8.4. Phase II
8.5. Phase III
9. Global Dengue Vaccines Market, By Distribution Channel (USD Million) 2020-2033
9.1. Global Dengue Vaccines Market Size, Share and Forecast, By Distribution Channel, 2020-2026
9.2. Global Dengue Vaccines Market Size, Share and Forecast, By Distribution Channel, 2027-2033
9.3. Synthetic
9.4. Bio-Based
10. Global Dengue Vaccines Market Forecast, 2020-2033 (USD Million)
10.1. Global Dengue Vaccines Market Size and Market Share
11. Global Dengue Vaccines Market, By Region, 2020-2033 (USD Million)
11.1. Global Dengue Vaccines Market Size and Market Share By Region (2020-2026)
11.2. Global Dengue Vaccines Market Size and Market Share By Region (2027-2033)
11.3. Asia-Pacific
11.3.1. Australia
11.3.2. China
11.3.3. India
11.3.4. Japan
11.3.5. South Korea
11.3.6. Rest of Asia-Pacific
11.4. Europe
11.4.1. France
11.4.2. Germany
11.4.3. Italy
11.4.4. Spain
11.4.5. United Kingdom
11.4.6. Rest of Europe
11.5. Middle East and Africa
11.5.1. Kingdom of Saudi Arabia
11.5.2. United Arab Emirates
11.5.3. Qatar
11.5.4. South Africa
11.5.5. Egypt
12.5.6. Morocco
11.5.7. Nigeria
11.5.8. Rest of Middle-East and Africa
11.6. North America
11.6.1. Canada
11.6.2. Mexico
11.6.3. United States
11.7. Latin America
11.7.1. Argentina
11.7.2. Brazil
11.7.3. Rest of Latin America
12. Company Profile
12.1. Butantan Institute
12.1.1. Company details
12.1.2. Financial outlook
12.1.3. Product summary
12.1.4. Recent developments
12.2. GeneOne Life Science Inc.
12.2.1. Company details
12.2.2. Financial outlook
12.2.3. Product summary
12.2.4. Recent developments
12.3. GlaxoSmithKline Plc
12.3.1. Company details
12.3.2. Financial outlook
12.3.3. Product summary
12.3.4. Recent developments
12.4. Mylan N.V.
12.4.1. Company details
12.4.2. Financial outlook
12.4.3. Product summary
12.4.4. Recent developments
12.5. Medigen Vaccine Biologics Corporation
12.5.1. Company details
12.5.2. Financial outlook
12.5.3. Product summary
12.5.4. Recent developments
12.6. Merck and Co. Inc.
12.6.1. Company details
12.6.2. Financial outlook
12.6.3. Product summary
12.6.4. Recent developments
12.7. Nunn’s Home Medical Equipment Company Ltd.
12.7.1. Company details
12.7.2. Financial outlook
12.7.3. Product summary
12.7.4. Recent developments
12.8. Panacea Biotec Limited
12.8.1. Company details
12.8.2. Financial outlook
12.8.3. Product summary
12.8.4. Recent developments
12.9. Sanofi Pasteur Limited
12.9.1. Company details
12.9.2. Financial outlook
12.9.3. Product summary
12.9.4. Recent developments
12.10. Serum Institute of India Pvt. Ltd.
12.10.1. Company details
12.10.2. Financial outlook
12.10.3. Product summary
12.10.4. Recent developments
13. Conclusion
14. List of Abbreviations
15. Reference Links
SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.
The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.
